Live price temporarily unavailable.
Pasithea Therapeutics (KTTA) is a Health Care company. Latest news and coverage below.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $15.1K | $486.6K | — | — | — |
| Growth (year over year) | — | +3130.4% | — | — | — |
| Gross profit | −$2.21K | $373.4K | — | — | — |
| Gross margin | −14.7% | 76.7% | — | — | — |
| Operating income | −$4.51M | −$12.6M | −$16.0M | −$14.2M | −$20.9M |
| Operating margin | −29925.7% | −2587.3% | — | — | — |
| Net income | −$2.17M | −$13.9M | −$16.0M | −$13.9M | −$20.4M |
| Net margin | −14430.5% | −2864.3% | — | — | — |
| EPS (diluted) | −$0.21 | −$1.76 | −$0.42 | −$12.69 | −$2.91 |
| Balance sheet | |||||
| Cash and equivalents | $53.0M | $33.1M | $16.3M | $6.92M | $55.2M |
| Total assets | $53.3M | $45.2M | $26.1M | $16.1M | $60.2M |
| Total liabilities | $1.90M | $2.68M | $2.72M | $1.28M | $5.02M |
| Shareholders' equity | $51.4M | $42.5M | $23.4M | $14.8M | $55.2M |
| Cash flow | |||||
| Operating cash flow | −$3.17M | −$14.6M | −$12.8M | −$13.9M | −$15.2M |
| Capital expenditure | $21.5K | $107.1K | $34.3K | — | — |
| Free cash flow | −$3.20M | −$14.7M | −$12.8M | — | — |
| Share buybacks | — | — | $3.73M | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$3.00M | −$3.26M | −$3.68M | −$3.81M | −$3.11M | −$10.3M | −$4.88M | −$5.71M |
| Net income | −$3.00M | −$3.18M | −$3.56M | −$3.72M | −$3.04M | −$10.1M | −$2.87M | −$5.27M |
| EPS (diluted) | −$2.87 | −$2.41 | −$1.61 | −$0.66 | −$0.41 | −$0.23 | −$0.12 | −$0.16 |
| Balance sheet | ||||||||
| Cash and equivalents | $9.36M | $6.92M | $5.34M | $7.22M | $4.12M | $55.2M | $50.4M | $45.7M |
| Total assets | $18.6M | $16.1M | $14.7M | $17.0M | $13.6M | $60.2M | $56.4M | $51.7M |
| Total liabilities | $824.0K | $1.28M | $1.68M | $1.83M | $1.42M | $5.02M | $1.54M | $1.87M |
| Shareholders' equity | $17.8M | $14.8M | $13.0M | $15.2M | $12.2M | $55.2M | $54.8M | $49.8M |
| Cash flow | ||||||||
| Operating cash flow | −$3.12M | −$2.44M | −$3.06M | −$3.87M | −$2.89M | −$5.40M | −$4.79M | −$4.71M |
From Pasithea Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Pasithea Therapeutics in our feed yet.